(Date:10/10/2008)...ng point for behavior change, DES MOINES, Iowa, O...,Americans (51 percent) believe there are good thi...r changes are needed, according to the 2008,EBRI H...oday by the,Employee Benefit Research Institute an...derwritten by the Principal Financial Group(R)., ...
(Date:10/10/2008)...dentialing Center (ANCC) has designated Geisinger ...s came via a conference call to hospital administr...and applause., GMC joins an elite group of only 1...n the United States that have achieved Magnet stat...s recognition., "Achieving Magnet designation is ...
(Date:10/10/2008)... blame , , FRIDAY, Oct. 10 (HealthDay Ne...ve diabetes, being depressed was associated with a..., Publishing in the October issue of the Journal...he University of Washington tracked 10,704 Medicar...d diabetes and were enrolled in a disease manageme...
(Date:10/10/2008)...llence in the implementation of electronic health ...agement Systems Society (HIMSS) announces the reci...onal, Ambulatory and Community Health Organization...L (PRWEB) October 10, 2008 -- Honoring excellence ... (EHRs), the Healthcare Information and Managemen...
Breaking Medicine News(10 mins):Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 2Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 3Health News:Geisinger Medical Center earns prestigious Magnet designation 2Health News:Older Diabetics With Depression Face Higher Death Rate 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5...e government still mulling over the inclusion of g...edges, a tobacco company has raised the ire of ant...f cigarettes in tins which carry health warnings i...sily removed. Action on Smoking and Health (ASH)...
...o are on oral bisphosphonates, a treatment measure...nd Paget's disease of bone, should be told about t...e , according to guidelines published in this mont...ociation (ADA). Relying on a small but growing n...
... of women, especially moms, suffer from stress uri...g, coughing or even laughing can lead to urine lea...ve therapies, such as learning better bladder habi...sing problems such as chronic coughing, infections...
...ty of North Carolina researchers have found that D...hampoos and other personal care products//, seems ... mice. The ingredient was applied to the skin of p...verse effect on their offspring. Dr. Steven Zeisel...
Other Medicine News:(Date:10/8/2008)...e, Oct. 8 /- Vical Incorporated (Nasd...data and new nonclinical data,demonstrating that t...applicable in DNA- and protein-based infectious di...Alain P. Rolland, Pharm.D., Ph.D., Vical,s,Senior ...t the data today,Wednesday, October 8, at the Wor...
(Date:10/7/2008)...as, Oct. 7 /- The Texas Cardiac Arrhy...er has been selected as one of,only a few sites in...ical,trial for a new device to treat persistent at...t, training and research center specializing in he... David,s Medical Center and,Texas Cardiovascular C...
(Date:10/7/2008)...al study of adults, VYVANSE taken once-daily signi...week, PHILADELPHIA, Oct. 7 /PRNewswire-FirstCall/...l specialty biopharmaceutical company, today,annou... of the Journal of,Clinical Psychiatry found once-...icit Hyperactivity Disorder (ADHD) symptoms in adu...
(Date:10/7/2008)...tracts highlighting CIMZIA,s long-term benefits an...ents presented at American College,of Gastroentero...tCall/ -- Data from two studies,presented this wee...gy,(ACG) Annual Meeting demonstrate that CIMZIA(R)...F alpha (Tumor Necrosis Factor alpha) - provides,s...
Breaking Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9New study sheds light on Gal 26 23225 3Bpagos hawk evolutionary history 641 1New study sheds light on Gal 26 23225 3Bpagos hawk evolutionary history 641 2First significant genetic finding in severe PMS or PMDD 2600 1First significant genetic finding in severe PMS or PMDD 2600 2Algorithms to reanimate the heart 2598 1Algorithms to reanimate the heart 2598 2Algorithms to reanimate the heart 2598 3Dietary calcium could possibly prevent the spread of breast cancer to bone 639 1Dietary calcium could possibly prevent the spread of breast cancer to bone 639 2...SINESS WIRE)--Jun 25, 2007 - Neurogen,Corporation ...esults from two dose-ranging, Phase 2b clinical tr...,s proprietary insomnia agent,NG2-73, an alpha-3 ...lations were studied in each trial to determine th...ntenance of sleep,through the night without residu...
...hly potent DPP-4 inhibitor, possessing Ki of 27,pM...armaceuticals,Inc., a privately held drug discove...results of its potent, smart DPP-4 inhibitor,ARI-...n Diabetes,Association meeting in Chicago, Illinoi...y long acting, potent inhibitor of DPP-4 and,produ...
Other Medicine Technology:Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 2Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 3Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 4Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 5Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 6Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 7Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 8Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA 2Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA 3Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA 4... your own cath lab? Worried about the high costs,...adaches of managing the ongoing business operation... service leaving you free to care for your patient...venient diagnostic facility for you and your patie...
...s exactly the same as the model SP-8800 with one b...achy mode. This mode has its own fixation targets .... It allows you to select an area on the cornea to...are to calculate averages of multiple readings in ...
...rSuite holmium laser combines excellent cutting, a...rtually bloodless procedures. It is also extremely... stones of all compositions, making it an ideal mu...is transmitted through flexible fibers, it is espe...
...rSuite holmium laser combines excellent cutting, a...rtually bloodless procedures. It is also extremely... stones of all compositions, making it an ideal mu...is transmitted through flexible fibers, it is espe...
Medicine Products: